title: A trial of individual dose intensity and relative performance factors in tegafur maintenance chemotherapy for head and neck cancer.
abstract: Tegafur (Sunfural-S), as masked compound of a 5-fluorouracil derivative, was administered orally as a maintenance chemotherapeutic agent at a dose of 600 mg/day in 98 cases of head and neck epithelial cancer. The effectiveness of the drug was evaluated by a statistical method involving two formulae: individual dose intensity (IDI) and relative performance (RP). When comparing patients rated above a reference IDI value of 1.0 with those rated below 1.0, it was not possible to predict patient survival or tumor-free rates. In contrast, the value of the RP did show such a correlation. These findings support the effectiveness of Tegafur as a maintenance chemotherapeutic treatment for head and neck cancer patients.
authors.affiliation: Department of Otolaryngology, School of Medicine, Yokohama City University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Sawaki
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: T
authors.initials: T
authors.lastname: Shin
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: S
authors.initials: S
authors.lastname: Komiyama
authors.forename: T
authors.initials: T
authors.lastname: Umezaki
authors.forename: I
authors.initials: I
authors.lastname: Nahm
mesh_terms: D000368:Aged; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D005641:Tegafur